(NASDAQ: ADAG) Adagene's forecast annual revenue growth rate of 382.05% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 117.67%, and it is also forecast to beat the US market's average forecast revenue growth rate of 22.81%.
Adagene's revenue in 2026 is $103,204.On average, 7 Wall Street analysts forecast ADAG's revenue for 2026 to be $270,415,659, with the lowest ADAG revenue forecast at $0, and the highest ADAG revenue forecast at $1,113,476,244. On average, 7 Wall Street analysts forecast ADAG's revenue for 2027 to be $325,559,245, with the lowest ADAG revenue forecast at $0, and the highest ADAG revenue forecast at $1,113,476,244.
In 2028, ADAG is forecast to generate $751,154,609 in revenue, with the lowest revenue forecast at $0 and the highest revenue forecast at $3,092,989,568.